Abstract
Rituximab is a mouse/human chimeric IgG1κ monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B-lymphocytes. The mechanisms of action of rituximab involve complement-dependent cytotoxicity (CDC), complement-dependent cellular cytotoxicity (CDCC), antibody dependent cellular cytotoxicity (ADCC) and induction of apoptosis. Pharmacokinetic issues, tumor and molecular related factors mediate resistance to rituximab. Optimizing rituximab treatment requires a therapeutic project that might ideally be individualized and that includes enhancing of ADCC and CDC mechanisms, acting over apoptosis-regulating proteins and using synergistic conventional chemotherapeutic agents. Pharmacokinetic favourable schedules in specific diseases alone or associated to chemotherapeutic agents are not well known, therefore studies focusing on these issues are warranted. New information regarding targeting the lymphoma microenvironment and rituximab effects is the focus of current research.
Keywords: Rituximab, lymphoma, treatment, pharmacokinetic
Reviews on Recent Clinical Trials
Title: Pharmacokinetic Properties of Rituximab
Volume: 3 Issue: 1
Author(s): Jose Rodriguez and Antonio Gutierrez
Affiliation:
Keywords: Rituximab, lymphoma, treatment, pharmacokinetic
Abstract: Rituximab is a mouse/human chimeric IgG1κ monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B-lymphocytes. The mechanisms of action of rituximab involve complement-dependent cytotoxicity (CDC), complement-dependent cellular cytotoxicity (CDCC), antibody dependent cellular cytotoxicity (ADCC) and induction of apoptosis. Pharmacokinetic issues, tumor and molecular related factors mediate resistance to rituximab. Optimizing rituximab treatment requires a therapeutic project that might ideally be individualized and that includes enhancing of ADCC and CDC mechanisms, acting over apoptosis-regulating proteins and using synergistic conventional chemotherapeutic agents. Pharmacokinetic favourable schedules in specific diseases alone or associated to chemotherapeutic agents are not well known, therefore studies focusing on these issues are warranted. New information regarding targeting the lymphoma microenvironment and rituximab effects is the focus of current research.
Export Options
About this article
Cite this article as:
Rodriguez Jose and Gutierrez Antonio, Pharmacokinetic Properties of Rituximab, Reviews on Recent Clinical Trials 2008; 3 (1) . https://dx.doi.org/10.2174/157488708783330495
DOI https://dx.doi.org/10.2174/157488708783330495 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer
Current Cancer Therapy Reviews HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Isolation, Purification, Characterisation and Application of L-ASNase: A Review
Recent Patents on Biotechnology A Novel Synthesis Method of Apogossypolone and its Antitumor Activity
Letters in Drug Design & Discovery Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
Current Drug Metabolism The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Concentration-Dependent Bimodal Effect of Specific 18 kDa Translocator Protein (TSPO) Ligands on Cell Death Processes Induced by Ammonium Chloride: Potential Implications for Neuropathological Effects Due to Hyperammonemia
CNS & Neurological Disorders - Drug Targets An Approach to Whole-Genome Identification of IRES Elements
Current Genomics Genetic Techniques for Pharmacogenetic Analyses
Current Pharmaceutical Design Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Synthesis and Biological Potential Assessment of 2-Substituted Quinazolin-4(3<i>H</i>)-ones as Inhibitors of Phosphodiesterase-I and Carbonic Anhydrase-II
Medicinal Chemistry Computational Tools in the Discovery of New G-Quadruplex Ligands with Potential Anticancer Activity
Current Topics in Medicinal Chemistry Update on MDS Therapy: From Famine to Feast
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types
Current Cancer Drug Targets Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Current Medicinal Chemistry